Although immunotherapy drugs may now provide a treatment option for older patients with cancer who are ineligible for, or whose disease fails, chemotherapy, there are many unanswered questions about the efficacy and adverse effects of immunotherapy in this patient population.
Supriya G. Mohile, MD, MS, associate professor of medicine at the James Wilmot Cancer Center at the University of Rochester, is the recipient of the 2018 B.J. Kennedy Award for Scientific Excellence in Geriatric Oncology.
Multiple studies have found that people age 65 and older are underrepresented in both cancer registration trials and the National Cancer Institute’s National Clinical Trials Network (NCTN) clinical trials, with only modest improvement over time.
Dr. Daneng Li discusses his experience with incorporating geriatric assessment tools and life expectancy calculators into his clinical practice to help guide the shared decision-making process for older adult patients.